This is a routine CFO appointment with no immediate stock-moving implications. Monitor for any future capital markets activity or strategic transactions that Mr. Levine's background may facilitate.
Price Chart
Executive Summary
Kazia Therapeutics announced the appointment of James Levine as Chief Financial Officer, effective June 1, 2026. Mr. Levine brings extensive biotech finance and investment banking experience, including former CFO roles at Cardiff Oncology and Cidara Therapeutics, where he structured major licensing collaborations. The filing is a routine executive appointment with no financial results or material corporate events.
Key Facts
- James Levine appointed CFO effective June 1, 2026
- Annual base salary of US$475,000 with target bonus of 40%
- Subject to Board approval, will receive options over 200,000 ADSs with 1/3 vesting upon commencement
- Mr. Levine previously served as CFO of Cardiff Oncology and Cidara Therapeutics, and spent 12 years at Goldman Sachs as a Managing Director
Financial Impact
No financial impact from this executive appointment; compensation is standard for a public biotech CFO role
Risk Factors
- No material risks identified from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-063820 |
| Document: ea0293115-6k_kazia.htm | 0001213900-26-063820 |
| Document: ea029311501ex99-1.htm | 0001213900-26-063820 |
| Document: 0001213900-26-063820-index-headers.html | 0001213900-26-063820 |
| Document: 0001213900-26-063820-index.html | 0001213900-26-063820 |
| Document: 0001213900-26-063820.txt | 0001213900-26-063820 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 24d ago | SC 13G/A | $9.27 | awaiting T+20 | — | $8.31 (−10.36%) |
Sep 22, 2026 5w ago | 6-K | $10.92 $7.88 | ▼ −27.84% | ▼ −27.28% | $8.31 (−23.90%) |
Sep 1, 2026 7w ago | 6-K | $12.61 $9.60 | ▼ −23.91% | ▼ −23.58% | $8.31 (−34.10%) |
Aug 31, 2026 8w ago | Press Release | $12.63 $9.60 | ▲ +24.03% | ▲ +24.35% | $8.31 (+34.20%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▼ −29.19% | ▼ −29.01% | $8.31 (−39.65%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $8.31 (+39.65%) |
Aug 31, 2026 8w ago | 424B5 | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $8.31 (+39.65%) |
Aug 28, 2026 8w ago | 6-K / 424B5 | $13.58 $9.60 | ▲ +29.31% | ▲ +29.57% | $8.31 (+38.81%) |
Aug 28, 2026 8w ago | 424B5 | $13.58 $9.60 | ▼ −29.31% | ▼ −29.57% | $8.31 (−38.81%) |
Jul 28, 2026 13w ago | 6-K | $12.69 $13.79 | ▲ +8.67% | ▲ +5.29% | $8.31 (−34.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers